133 related articles for article (PubMed ID: 14710346)
1. Impact of IGF-I/IGF-IR circuit on the angiogenetic properties of Ewing's sarcoma cells.
Strammiello R; Benini S; Manara MC; Perdichizzi S; Serra M; Spisni E; Picci P; Scotlandi K
Horm Metab Res; 2003; 35(11-12):675-84. PubMed ID: 14710346
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells.
Benini S; Manara MC; Baldini N; Cerisano V; Massimo Serra ; Mercuri M; Lollini PL; Nanni P; Picci P; Scotlandi K
Clin Cancer Res; 2001 Jun; 7(6):1790-7. PubMed ID: 11410521
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family.
Dalal S; Berry AM; Cullinane CJ; Mangham DC; Grimer R; Lewis IJ; Johnston C; Laurence V; Burchill SA
Clin Cancer Res; 2005 Mar; 11(6):2364-78. PubMed ID: 15788688
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target.
Scotlandi K; Benini S; Sarti M; Serra M; Lollini PL; Maurici D; Picci P; Manara MC; Baldini N
Cancer Res; 1996 Oct; 56(20):4570-4. PubMed ID: 8840962
[TBL] [Abstract][Full Text] [Related]
5. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones.
Guo Y; Wang S; Hoot DR; Clinton SK
J Nutr Biochem; 2007 Jun; 18(6):408-17. PubMed ID: 17142033
[TBL] [Abstract][Full Text] [Related]
6. Expression of granulocyte-colony-stimulating factor and its receptor in human Ewing sarcoma cells and patient tumor specimens: potential consequences of granulocyte-colony-stimulating factor administration.
Morales-Arias J; Meyers PA; Bolontrade MF; Rodriguez N; Zhou Z; Reddy K; Chou AJ; Koshkina NV; Kleinerman ES
Cancer; 2007 Oct; 110(7):1568-77. PubMed ID: 17694551
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: effects on insulin-like growth factor II.
Braczkowski R; Schally AV; Plonowski A; Varga JL; Groot K; Krupa M; Armatis P
Cancer; 2002 Oct; 95(8):1735-45. PubMed ID: 12365022
[TBL] [Abstract][Full Text] [Related]
8. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model.
Guan H; Zhou Z; Wang H; Jia SF; Liu W; Kleinerman ES
Clin Cancer Res; 2005 Apr; 11(7):2662-9. PubMed ID: 15814647
[TBL] [Abstract][Full Text] [Related]
9. VEGF(165), but not VEGF(189), stimulates vasculogenesis and bone marrow cell migration into Ewing's sarcoma tumors in vivo.
Zhou Z; Reddy K; Guan H; Kleinerman ES
Mol Cancer Res; 2007 Nov; 5(11):1125-32. PubMed ID: 18025258
[TBL] [Abstract][Full Text] [Related]
10. Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma.
Manara MC; Landuzzi L; Nanni P; Nicoletti G; Zambelli D; Lollini PL; Nanni C; Hofmann F; García-Echeverría C; Picci P; Scotlandi K
Clin Cancer Res; 2007 Feb; 13(4):1322-30. PubMed ID: 17317844
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of Id-1 in prostate cancer cells promotes angiogenesis through the activation of vascular endothelial growth factor (VEGF).
Ling MT; Lau TC; Zhou C; Chua CW; Kwok WK; Wang Q; Wang X; Wong YC
Carcinogenesis; 2005 Oct; 26(10):1668-76. PubMed ID: 15905202
[TBL] [Abstract][Full Text] [Related]
12. Suppression of Ewing's sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy.
Zhou Z; Bolontrade MF; Reddy K; Duan X; Guan H; Yu L; Hicklin DJ; Kleinerman ES
Clin Cancer Res; 2007 Aug; 13(16):4867-73. PubMed ID: 17699866
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of N-linked glycosylation down-regulates insulin-like growth factor-1 receptor at the cell surface and kills Ewing's sarcoma cells: therapeutic implications.
Girnita L; Wang M; Xie Y; Nilsson G; Dricu A; Wejde J; Larsson O
Anticancer Drug Des; 2000 Feb; 15(1):67-72. PubMed ID: 10888037
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effect of nutrient synergy on human osteosarcoma cells U-2OS, MNNG-HOS and Ewing's sarcoma SK-ES.1.
Roomi MW; Ivanov V; Kalinovsky T; Niedzwiecki A; Rath M
Oncol Rep; 2005 Feb; 13(2):253-7. PubMed ID: 15643507
[TBL] [Abstract][Full Text] [Related]
15. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice.
Scotlandi K; Benini S; Nanni P; Lollini PL; Nicoletti G; Landuzzi L; Serra M; Manara MC; Picci P; Baldini N
Cancer Res; 1998 Sep; 58(18):4127-31. PubMed ID: 9751624
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha are expressed in kaposi sarcoma and modulated by insulin-like growth factor-I.
Catrina SB; Botusan IR; Rantanen A; Catrina AI; Pyakurel P; Savu O; Axelson M; Biberfeld P; Poellinger L; Brismar K
Clin Cancer Res; 2006 Aug; 12(15):4506-14. PubMed ID: 16899596
[TBL] [Abstract][Full Text] [Related]
17. Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects.
Benini S; Manara MC; Cerisano V; Perdichizzi S; Strammiello R; Serra M; Picci P; Scotlandi K
Int J Cancer; 2004 Jan; 108(3):358-66. PubMed ID: 14648701
[TBL] [Abstract][Full Text] [Related]
18. Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype.
Xie Y; Skytting B; Nilsson G; Brodin B; Larsson O
Cancer Res; 1999 Aug; 59(15):3588-91. PubMed ID: 10446966
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.
Scotlandi K; Manara MC; Nicoletti G; Lollini PL; Lukas S; Benini S; Croci S; Perdichizzi S; Zambelli D; Serra M; García-Echeverría C; Hofmann F; Picci P
Cancer Res; 2005 May; 65(9):3868-76. PubMed ID: 15867386
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid.
Gee MF; Tsuchida R; Eichler-Jonsson C; Das B; Baruchel S; Malkin D
Oncogene; 2005 Dec; 24(54):8025-37. PubMed ID: 16116481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
